CompanyLGVNNasdaqMiami, FL

Longeveron Inc.

Longeveron develops laromestrocel, an allogeneic mesenchymal stem cell therapy derived from donor bone marrow.

SEC EDGAR ClinicalTrials.gov longeveron.com

424B3Sep 25Latest SEC filing

Sep 23Latest story

September 2026

Longeveron's ELPIS II trial misses primary endpoint in HLHS study

Sep 23Clinical readoutLongeveron Inc.

August 2026

Longeveron names Nirav Jhaveri as chief financial officer

Aug 19PeopleLongeveron Inc.

Longeveron reports Q2 2026 results, keeps September readout for HLHS heart trial

Aug 12Quarterly updateLongeveron Inc.

July 2026

Longeveron names Marie Washburn as CFO, revises CEO pay, grants Executive Chairman equity

Jul 14PeopleLongeveron Inc.